MX2019006940A - Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. - Google Patents

Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.

Info

Publication number
MX2019006940A
MX2019006940A MX2019006940A MX2019006940A MX2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A
Authority
MX
Mexico
Prior art keywords
bipolar disorder
relief
prevention
treatment
carbamate compounds
Prior art date
Application number
MX2019006940A
Other languages
English (en)
Spanish (es)
Inventor
Jin Shin Yu
Myoung Han Sei
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2019006940A publication Critical patent/MX2019006940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019006940A 2016-12-14 2017-12-14 Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. MX2019006940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
MX2019006940A true MX2019006940A (es) 2019-09-06

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006940A MX2019006940A (es) 2016-12-14 2017-12-14 Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003203A (es) * 2018-09-21 2021-05-27 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
KR20220104746A (ko) * 2019-11-22 2022-07-26 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297732C (en) * 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
KR100843703B1 (ko) 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
CZ20032300A3 (cs) * 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
HUP0303261A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating bipolar disorder
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2667909A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
BRPI0924997B1 (pt) 2009-06-22 2024-01-16 Sk Biopharmaceuticals Co., Ltd Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9981950B2 (en) * 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors

Also Published As

Publication number Publication date
EP3556366A1 (en) 2019-10-23
RU2019121913A (ru) 2021-01-15
JP2020502106A (ja) 2020-01-23
ZA201903747B (en) 2021-01-27
WO2018111008A1 (ko) 2018-06-21
KR102635938B1 (ko) 2024-02-13
CL2019001618A1 (es) 2019-08-23
AU2017374458B2 (en) 2023-03-02
US11571410B2 (en) 2023-02-07
RU2019121913A3 (enExample) 2021-04-21
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
IL267195A (enExample) 2019-07-31
KR20190087572A (ko) 2019-07-24
CA3046297A1 (en) 2018-06-21
BR112019011930A2 (pt) 2019-10-29
EP3556366B1 (en) 2025-10-22
CN110290788A (zh) 2019-09-27
US20190314337A1 (en) 2019-10-17
ES3054693T3 (en) 2026-02-05
IL267195B1 (en) 2024-01-01
MY199104A (en) 2023-10-13
AU2017374458A1 (en) 2019-07-04
JP7208139B2 (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
PH12021500034A1 (en) Compounds useful in hiv therapy
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
MX392555B (es) Composiciones y métodos para el tratamiento de resistencia a la insulina.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.